171 results
Page 4 of 9
8-K
EX-99.1
x9xlkf3v4ub9w
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
ru54nfpj
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
EX-99.1
2amlo 26dvg7nyqlxo
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
fozgz6y pfxd0rb
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
1tzgy
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
33fo5 6gaad
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
yj82t
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
EX-1.2
qjyk5
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-99.1
tdd7qzg87n2 7ukiwnle
6 Aug 20
Adaptimmune Reports Q2 Financial Results and Business Update
7:37am
8-K
EX-1.1
ckqrmh4
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
dab85455zf4c3 qi
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.2
447zc0b15
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-99.1
cgd bj8e0df2b15t2
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
zbd85vz5
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
ve0grk 4cyd0wj
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
EX-99.1
8eqgj j0w9
29 Apr 20
Other Events
8:06am